ImmunityBio: The Story Surrounding Anktiva So Far

2026-02-18 05:12:10 ET

Thesis

ImmunityBio, Inc. ( IBRX ) stock has been on a very bullish run. The investor confidence comes from the potential of a chemo?free immunotherapy platform, which is led by Anktiva. The short idea here is that Anktiva is an IL?15 superagonist that fuels and sustains NK and T cells without the toxicity we get from chemotherapy or lymphodepletion. The market now has massive expectations, which is where the risk lies. The early clinical data are presented across several cancer types, particularly in recurrent glioblastoma and indolent lymphomas, which show promising immune activation with a manageable safety profile. The main signals investors want to see are potential survival benefits, which can exceed historical norms. Elsewhere, mOS has not yet been reached in glioblastoma, but lymphocyte counts were seen to be restored within one cycle....

Read the full article on Seeking Alpha

For further details see: